Bob Oliver, President and CEO, Otsuka America Pharmaceutical, Inc.
The impact of big data is being felt in every industry, but the impact on pharma is amplified by the convergence of science and technology.
Margaretta Nyilas, MD, Senior Vice President, Clinical Management & Business Operations, Otsuka Pharmaceutical Development & Commercialization. Inc.
The steady pace of new disruptive technologies continues to transform our personal lives, as businesses also continue to realize increasing efficiencies and cost reductions.
Michael Murphy, Chief Medical and Scientific Officer, Worldwide Clinical Trials
In its genesis CRO and sponsor relationships were built around single points of contact, an overflow and capacity based business model with a “feast versus famine” business cycle and a transactional exchange of services....
Jason Burke, System VP, Enterprise Analytics & Data Sciences, UNC Health Care
Why can we predict hurricanes and snow storms days to weeks in advance, but healthcare struggles to know what will be happening with patients tomorrow?
Temitope Keyes, VP of Business Development, ThoughtSphere
It is hard to think of an industry that has not, or could not, benefit from the scalability and ease of cloud technology.
Ron Guido, VP Regulatory Affairs, IRX Therapeutics
The emergence of biosimilars has highlighted the challenges involved in manufacturing large, complex biological products.
Steve Cutler, COO, ICON plc [NASDAQ:ICLR]
Electronic Health Records (EHRs) exist to aid in the delivery of care and the administration of health systems.
James Streeter, Global VP Life Sciences Strategy, Oracle Health Sciences
It's a logical conclusion that expanding data sources in clinical trials can lead to more therapies, but does this additional data speed up or slow down a clinical trial?
Christy Wilson, Senior Director, Pharma and Biotech Segment, Elsevier’s R&D Solutions
For pharmaceutical companies, the safety of their products is of paramount concern.